Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sotorasib in KRAS p.G12C mutant advanced solid tumors
NCT04185883Phase 1Active, not recruiting
- Sponsor
- Amgen
- Start
- Dec 2019
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 13
01
Overview
Phase 1, open-label trial of sotorasib in solid tumor (advanced stage) (14 arms), sponsored by Amgen. Primary endpoints: Dose Limiting Toxicities at 12 months, Treatment-emergent Adverse Events at 12 months and 4 more. Started Dec 2019; status: active, not recruiting.
02
Drugs
sotorasib
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT04185883.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04185883.